Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Study of outcomes in frail patients getting bispecifics finds best ORR 80% in frail vs 73% in non-frail group; no significant difference in median PFS (NR vs 11 mos) or OS (37 vs 25 mos); similar rates of all grade CRS and ICANS.”
Title: Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Authors: Benjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, Ross S Firestone, Eric Matthew Jurgens, Kevin C. Miller, Alexander M Lesokhin, Gunjan L Shah, Neha Korde, Sridevi Rajeeve, Heather J Landau, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A Shah, Malin L Hultcrantz, Issam S. Hamadeh, Andriy Derkach, David Nemirovsky, Sergio A. Giralt, Sham Mailankody, Saad Z Usmani, Hamza Hashmi.
You can read the Full Article on Blood Advances.
More posts featuring Robert Orlowski.
